UCSF reports sustained suppression with long-acting HIV combination

UCSF researchers report sustained viral suppression in 46 patients given a long-acting lenacapavir and cabotegravir combination. The single-center retrospective study included people with treatment resistance or adherence difficulties. The combination is not approved as an HIV treatment regimen, and the findings need testing in controlled trials.